Oncology, the second largest therapeutic market in the U.S., is growing significantly faster than the pharmaceutical sector overall. Notably, much of this growth stems from new indications for existing therapies, a trend beginning to dominate oncology drug approvals. In response, companies in the oncology space are focusing on both growing their oncology business through novel therapies as well as indication expansion of existing products.

This white paper from the experts at Syneos Health® outlines the key considerations to keep in mind when prioritizing multiple indication opportunities in oncology and maximizing commercial opportunity.